Trial Profile

Phase III clinical trial of BTI 320 [PAZ 320] for type 2 diabetes mellitus

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 12 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BTI 320 (Primary) ; Dipeptidyl peptidase 4 inhibitors; Insulins; Metformin; Sulfonylureas
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Sponsors Boston Therapeutics; Nanomix Corporation

Most Recent Events

26 Apr 2017 According to a Boston Therapeutics media release, recruitment will initiate at the Joslin Diabetes Center, Boston, MA, and will be joined by its former trial center form the Chinese University of Hong Kong (CUHK) . The plans anticipate up to 10 additional institutions from the US and greater China.
10 Dec 2014 The US FDA has accepted the IND for this trial, according to a Boston Therapeutics media release.
06 May 2014 Status changed from unconfirmed to planning, according to a Boston Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com